Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.55 |
| ▸ | DHFR | P00374 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3560308 | 0.84 | HDAC1 (0.55) | HDAC1DHFRALDH1A1MAPTKDM4E | |
| SCHEMBL2733855 | 0.81 | HDAC1 (0.68) | HDAC1NAMPTHDAC2 | |
| SCHEMBL3975276 | 0.80 | LMNA (0.64) | HDAC1ALDH1A1MAPTKDM4ETDP1 | |
| SCHEMBL1081112 | 0.77 | TUBB4A (0.53) | HDAC1DHFRALDH1A1MAPTKDM4E | |
| SCHEMBL1064897 | 0.76 | NR1H4 (0.67) | HDAC1ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL3560484 | 0.76 | LMNA (0.56) | HDAC1DHFRALDH1A1MAPTKDM4E | |
| SCHEMBL1064412 | 0.74 | L3MBTL1 (0.53) | HDAC1DHFRALDH1A1MAPTKDM4E | |
| SCHEMBL21697974 | 0.74 | L3MBTL1 (0.53) | HDAC1DHFRALDH1A1MAPTKDM4E | |
| SCHEMBL10374158 | 0.73 | CA2 (0.56) | HDAC1CA2TBXAS1 | |
| SCHEMBL1888929 | 0.73 | HDAC1 (0.69) | HDAC1ALDH1A1KDM4ETDP1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885DHFR 460/4885ALDH1A1 680/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885DHFR 386/4885ALDH1A1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.